Investigating the Role of Delta‑Like 1 Homolog (Dlk1) in T Cell Immune Surveillance and Tumor Progression of Hepatocellular Carcinoma

  • Huang, Chao-Cheng (PI)
  • Chu, Tian-Huei  (CoPI)
  • Hu, Tsung Hui (CoPI)
  • Tai, Ming Hong (CoPI)

Project: National Science and Technology Council › National Science and Technology Council Academic Grants

Project Details

Abstract

第一線口服用藥sorafenib和lenvatinib針對晚期肝癌的治療效果不彰，而目前療效最佳的免疫治療(atezolizumab)合併抗血管新生藥物的客觀反應率(ORR)只有約27%。因此開發新的肝癌免疫治療標靶與生物標誌是迫切需要的工作。本計畫將蒐集臨床肝癌腫瘤與血液來探討DLK1表現與免疫逃脫及預後的相關性，並利用免疫健全的肝癌動物模式驗證DLK1作為新肝癌免疫治療標靶的可能性。最後，利用肝癌細胞與T細胞共培養系統來研究DLK1調控腫瘤免疫逃脫的機制。期望此計畫的研究成果能進一步開發DLK1抗體藥物或阻斷劑作為新的肝癌免疫治療製劑，達成提升國人健康、學術地位和和產業發展的終極目標。

Project IDs

Project ID:PC11207-1484
External Project ID:NSTC112-2320-B182-030-MY3
StatusFinished
Effective start/end date01/08/23 → 31/07/24

Access Project

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint